Armata Pharmaceuticals (ARMP) Cash from Financing Activities (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 13 years of Cash from Financing Activities data on file, last reported at $641000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 93.58% year-over-year to $641000.0; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (up 62.46% YoY), and the FY2025 full-year result was $25.6 million, down 26.73% from the prior year.
• Cash from Financing Activities retreated to $641000.0 in Q1 2026, from $658000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $44.6 million in Q1 2022 to a low of -$500000.0 in Q4 2022.
• A 5-year average of $10.6 million and a median of $641000.0 in 2026 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 79916.13% in 2023, while the deepest fall reached 152.05% in 2023.
• Tracing ARMP's Cash from Financing Activities over 5 years: stood at -$500000.0 in 2022, then soared by 91.4% to -$43000.0 in 2023, then slumped by 41.86% to -$61000.0 in 2024, then surged by 1178.69% to $658000.0 in 2025, then declined by 2.58% to $641000.0 in 2026.
• Business Quant data shows ARMP's Cash from Financing Activities at $641000.0 in Q1 2026, $658000.0 in Q4 2025, and $15.0 million in Q3 2025.